시장보고서

상품코드

1454099

심막 질환 시장 : 유형별, 진단 방법별, 치료 접근법별, 최종 사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 및 예측(2024-2032년)

Pericardium Diseases Market, By Type, By Diagnosis Method, By Treatment Approach, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 03월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 285 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

심막 질환 시장 규모는 2023년 24억 4,100만 달러로 평가되었고, 2024년부터 2032년까지 연평균 5.7% 성장할 것으로 예상됩니다.

심막 질환 시장 - 시장 역학

심혈관 질환의 유병률 증가가 시장 성장을 주도할 것으로 예상됩니다.

좌식 생활습관, 식습관의 변화, 고령화 등으로 인해 심혈관 질환의 유병률은 전 세계적으로 증가 추세에 있습니다. 이에 따라 심막 질환의 진단 및 치료 옵션에 대한 수요가 급증할 것으로 예상됩니다. 세계보건기구(WHO)의 보고에 따르면, 심혈관계 질환(CVD)은 전 세계 사망의 주요 원인으로 연간 약 1,790만 명의 목숨을 앗아가고 있습니다. 연구개발에 대한 지속적인 투자는 시장 확대의 잠재력을 가지고 있습니다. 하지만, 높은 치료비용이 시장 성장을 저해하는 요인으로 작용할 수 있습니다.

심막 질환 시장 - 주요 인사이트

당사의 리서치 애널리스트의 분석에 따르면, 세계 시장은 예측 기간(2024-2032년) 동안 연평균 약 5.7%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

시장 세분화에서 비스테로이드성 항염증제(NSAIDS)는 2023년 가장 큰 시장 점유율을 보일 것으로 예측됩니다.

치료 방식별로는 비스테로이드성 항염증제(NSAIDS)가 2023년 주요 유형으로 꼽혔습니다.

최종 사용자별로는 병원 및 클리닉이 2023년 주요 유형으로 꼽혔습니다.

지역별로는 북미가 2023년 매출 1위

심막 질환 시장 - 세분화 분석 :

세계 심막 질환 시장은 유형, 진단 방법, 치료 접근법, 최종 사용자 및 지역에 따라 세분화됩니다.

시장은 치료 방식에 따라 급성 심막염, 혈성 심막염, 심막염, 결핵성 심막염 등 두 가지 그룹으로 나뉩니다. 급성 심막염이 시장을 독점하고 있습니다. 급성 심막염은 갑자기 발생하는 심막의 염증이 특징이며, 종종 흉통, 발열, 호흡곤란 등의 증상을 유발합니다.

시장은 진단 방법에 따라 흉부 엑스레이, 심장 MRI, 심장 CT 스캔, 심초음파, 심전도, 기타(혈액 검사) 등 5가지 범주로 나뉩니다. 심막 질환의 평가에는 심막과 심장을 모두 평가하는 데 도움이 되는 다양한 기술이 포함됩니다.

시장은 치료 방식에 따라 비스테로이드성 항염증제(NSAIDs)와 심막 절제술의 두 가지 범주로 나뉩니다. 비스테로이드성 항염증제(NSAIDS) 부문은 시장을 독점하고 있습니다. 비스테로이드성 항염증제(NSAIDs)는 급성 심막염과 같은 질병의 관리 및 치료에 중요한 역할을 합니다.

시장은 최종 사용자에 따라 병원 및 클리닉, 외래 환자 센터 및 기타 두 가지 부문으로 나뉩니다. 시장의 지배적 인 부문은 병원 및 클리닉입니다. 이러한 의료 시설은 급성 심막염, 심막액 저류, 수축성 심막염, 심막 탐폰나드 등 다양한 심막 질환을 앓고 있는 환자에게 필수적인 의료 서비스를 제공하는 데 중요한 역할을 하고 있습니다.

심막 질환 시장 - 지리적 통찰력

시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카에 지리적으로 분포되어 있습니다. 이 지역들은 사업 활동을 하는 국가에 따라 더 세분화됩니다. 시장 성장을 주도하는 것은 북미가며, 그 주된 이유는 의료비 지출 증가에 기인합니다. 북미는 첨단 의료 인프라, 최첨단 의료 시설, 일류 연구 기관, 고도로 숙련된 의료 전문가를 보유하고 있습니다. 메디케어-메디케이드 서비스 센터에 따르면 미국의 의료비 지출은 2022년 4.1% 증가해 4조 5,000억 달러, 1인당 1만 3,493달러에 달할 것으로 예상했습니다. 의료비는 국내 총생산의 17.3%를 차지합니다. 유럽은 심막 질환 관리에 대한 수요 증가에 힘입어 시장 성장률 2위 지역으로 부상했습니다.

심막 질환 시장 - 경쟁 상황:

심막 질환 시장에는 심장을 감싸고 있는 보호막인 심막에 영향을 미치는 다양한 질환이 포함됩니다. 제약회사와 생명공학 기업들은 이러한 질환에 대한 새로운 치료법을 개발하기 위해 치열한 경쟁을 벌이고 있습니다. 이들은 대규모 전임상 및 임상시험에 투자하여 약물의 안전성과 유효성을 입증하고, 규제 당국의 승인을 받아 이 치료 분야에서 큰 시장 점유율을 확보하는 것을 최종 목표로 삼고 있습니다. 경쟁은 제품 개발에 그치지 않고 시장 진입과 상환 전략에도 영향을 미치고 있습니다. 각 업체들은 환자와 의료 서비스 제공업체가 자사 제품을 쉽게 이용할 수 있도록 지불자로부터 유리한 처방과 상환을 받기 위해 경쟁하고 있습니다.

서론
북미
- 개요
- 북미 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - 심막 질환 업계

경쟁 대시보드
기업 개요
- Kiniksa Pharmaceuticals
- Pfizer Inc.
- Medtronic
- Bayer AG
- AstraZeneca Plc
- Sanofi
- Johnson and Johnson Services, Inc.
- Merck &Co., Inc.
- Allergan Plc.
- Novartis AG
- Perkin Elmer Inc.
- Integra Lifesciencesk
- Others

제13장 애널리스트의 전방위 전망

LSH 24.04.30

REPORT HIGHLIGHT

Pericardium Diseases Market size was valued at USD 2,441 Million in 2023, expanding at a CAGR of 5.7% from 2024 to 2032.

Pericarditis is a prevalent medical issue characterized by inflammation of the pericardium, the delicate membrane enveloping the heart. Typically, there exists a small quantity of fluid between the inner and outer layers of the pericardium. In cases of inflammation, this fluid often increases. A significant accumulation of fluid can hinder the heart's ability to fill and operate effectively. Pericardial disease can either appear independently or as a symptom of a broader systemic ailment.

Pericardium Diseases Market- Market Dynamics

Increased prevalence of cardiovascular disorders is expected to dominate the growth of market

The prevalence of cardiovascular diseases is on the rise worldwide, attributed to sedentary lifestyles, poor dietary habits, and aging populations. Consequently, there is expected to be a surge in the need for diagnostic and therapeutic options for pericardial diseases. The World Health Organization reports that cardiovascular diseases (CVDs) are the primary cause of mortality globally, claiming approximately 17.9 million lives annually. Ongoing investments in research and development present potential for market expansion. Nevertheless, the high costs associated with treatment may impede market growth.

Pericardium Diseases Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.7% over the forecast period (2024-2032)

Based on Type segmentation, Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Drugs was predicted to show maximum market share in the year 2023

Based on Treatment Approach segmentation, Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Drugs was the leading type in 2023

Based on End-user Approach segmentation, hospitals and clinics was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Pericardium Diseases Market- Segmentation Analysis:

The Global Pericardium Diseases Market is segmented on the basis of Type, Diagnosis Method, Treatment Approach, End-User, and Region.

The market is categorized into two groups according to the Treatment Approach: Acute pericarditis, Hemopericardium, Pericarditis and Tuberculous pericarditis. Acute pericarditis dominates the market. Acute pericarditis is characterized by sudden onset inflammation of the pericardium, often resulting in symptoms such as chest pain, fever, and difficulty breathing.

The market is segmented into five categories according to the Diagnosis Method: Chest X-Ray, Cardiac MRI, Cardiac CT Scan, Echocardiography, Electrocardiography (EKG), and Others (Blood Test). The evaluation of pericardium diseases encompasses a range of techniques that aid in the assessment of both the pericardium and the heart.

The market is divided into two categories based on Treatment Approach: Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Drugs and Pericardiectomy. Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Drugs segment dominates the market. nonsteroidal anti-inflammatory drugs (NSAIDs) play a crucial role in the management and treatment of conditions such as acute pericarditis.

The market is categorized into two segments based on the end user: hospitals and clinics, ambulatory centers, and others. The dominant segment in the market is hospitals and clinics. These healthcare facilities play a crucial role in providing essential healthcare services to patients with various pericardial conditions, such as acute pericarditis, pericardial effusion, constrictive pericarditis, and pericardial tamponade, among others.

Pericardium Diseases Market- Geographical Insights

The market is geographically spread across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The growth of the market is dominated by North America, primarily due to the rising healthcare expenditure. North America takes pride in its advanced healthcare infrastructure, state-of-the-art medical facilities, leading research institutions, and highly skilled healthcare professionals. According to the Center for Medicare and Medicaid Services, healthcare spending in the United States grew by 4.1 percent in 2022, reaching USD4.5 trillion or USD13,493 per person. Health spending accounted for 17.3 percent of the nation's Gross Domestic Product. Europe holds the second-largest region for market growth, driven by the increased demand for pericardium disease management.

Pericardium Diseases Market- Competitive Landscape:

The pericardium diseases market encompasses a variety of conditions that impact the pericardium, the protective sac that surrounds the heart. Pharmaceutical and biotechnology companies engage in fierce competition as they strive to develop new therapies for these diseases. These companies invest in extensive preclinical and clinical studies to demonstrate the safety and effectiveness of their investigational drugs, with the ultimate goal of obtaining regulatory approvals and capturing a significant market share in this therapeutic field. The competition extends beyond the development of products and includes strategies for market access and reimbursement. Companies compete to secure favorable formulary placement and reimbursement coverage from payers, ensuring that their products are readily available to patients and healthcare providers.

Recent Developments:

In October 2023, Pfizer Inc. and BioNTech SE have reported encouraging top-line findings from a Phase 1/2 trial (NCT05596734) assessing the safety, tolerability, and immunogenicity of mRNA-based combination vaccine candidates targeting influenza and COVID-19 in a cohort of healthy adults aged 18 to 64 years.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PERICARDIUM DISEASES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Kiniksa Pharmaceuticals

Pfizer Inc.

Medtronic

Bayer AG

AstraZeneca Plc

Sanofi

Johnson and Johnson Services, Inc.

Merck & Co., Inc.

Allergan Plc.

Novartis AG

Perkin Elmer Inc.

Integra Lifesciencesk

Others

GLOBAL PERICARDIUM DISEASES MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

Acute pericarditis
Hemopericardium
Pericarditis
Tuberculous pericarditis

GLOBAL PERICARDIUM DISEASES MARKET, BY DIAGNOSIS METHOD- MARKET ANALYSIS, 2019 - 2032

Chest X-Ray
Cardiac MRI
Cardiac CT Scan
Echocardiography
Electrocardiography (EKG)
Others (Blood Test)

GLOBAL PERICARDIUM DISEASES MARKET, BY TREATMENT APPROACH- MARKET ANALYSIS, 2019 - 2032

Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Drugs
Pericardiectomy

GLOBAL PERICARDIUM DISEASES MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospital & clinics
Ambulatory centers
Others

GLOBAL PERICARDIUM DISEASES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1.Pericardium Diseases Market Overview

1.1.Study Scope
1.2.Market Estimation Years

2.Executive Summary

2.1.Market Snippet
- 2.1.1.Pericardium Diseases Market Snippet by Type
- 2.1.2.Pericardium Diseases Market Snippet by Diagnosis Method
- 2.1.3.Pericardium Diseases Market Snippet by Treatment Approach
- 2.1.4.Pericardium Diseases Market Snippet by End-User
- 2.1.5.Pericardium Diseases Market Snippet by Country
- 2.1.6.Pericardium Diseases Market Snippet by Region
2.2.Competitive Insights

3.Pericardium Diseases Key Market Trends

3.1.Pericardium Diseases Market Drivers
- 3.1.1.Impact Analysis of Market Drivers
3.2.Pericardium Diseases Market Restraints
- 3.2.1.Impact Analysis of Market Restraints
3.3.Pericardium Diseases Market Opportunities
3.4.Pericardium Diseases Market Future Trends

4.Pericardium Diseases Industry Study

4.1.PEST Analysis
4.2.Porter's Five Forces Analysis
4.3.Growth Prospect Mapping
4.4.Regulatory Framework Analysis

5.Pericardium Diseases Market: COVID-19 Impact Analysis

5.1.Pre-COVID-19 Impact Analysis
5.2.Post-COVID-19 Impact Analysis
- 5.2.1.Top Performing Segments
- 5.2.2.Marginal Growth Segments
- 5.2.3.Top Looser Segments
- 5.2.4.Marginal Loss Segments

6.Pericardium Diseases Market Landscape

6.1.Pericardium Diseases Market Share Analysis, 2023
6.2.Breakdown Data, by Key Manufacturer
- 6.2.1.Established Players' Analysis
- 6.2.2.Emerging Players' Analysis

7.Pericardium Diseases Market - By Type

7.1.Overview
- 7.1.1.Segment Share Analysis, By Type, 2023 & 2032 (%)
- 7.1.2.Acute pericarditis
- 7.1.3.Hemopericardium
- 7.1.4.Pericarditis
- 7.1.5.Tuberculous pericarditis

8.Pericardium Diseases Market - By Diagnosis Method

8.1.Overview
- 8.1.1.Segment Share Analysis, By Diagnosis Method, 2023 & 2032 (%)
- 8.1.2.Chest X-Ray
- 8.1.3.Cardiac MRI
- 8.1.4.Cardiac CT Scan
- 8.1.5.Echocardiography
- 8.1.6.Electrocardiography (EKG)
- 8.1.7.Others (Blood Test)

9.Pericardium Diseases Market - By Treatment Approach

9.1.Overview
- 9.1.1.Segment Share Analysis, By Treatment Approach, 2023 & 2032 (%)
- 9.1.2.Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Drugs
- 9.1.3.Pericardiectomy

10.Pericardium Diseases Market - By End-User

10.1.Overview
- 10.1.1.Segment Share Analysis, By End-User, 2023 & 2032 (%)
- 10.1.2.Hospital & clinics
- 10.1.3.Ambulatory centers
- 10.1.4.Others

11.Pericardium Diseases Market- By Geography

11.1.Introduction
- 11.1.1.Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2.North America
- 11.2.1.Overview
- 11.2.2.Pericardium Diseases Key Manufacturers in North America
- 11.2.3.North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4.North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.2.5.North America Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
- 11.2.6.North America Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
- 11.2.7.North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.8.U.S.
  - 11.2.8.1.Overview
  - 11.2.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3.U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4.U.S. Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.2.8.5.U.S. Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.2.8.6.U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.2.9.Canada
  - 11.2.9.1.Overview
  - 11.2.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3.Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4.Canada Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.2.9.5.Canada Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.2.9.6.Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.3.Europe
- 11.3.1.Overview
- 11.3.2.Pericardium Diseases Key Manufacturers in Europe
- 11.3.3.Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4.Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.3.5.Europe Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
- 11.3.6.Europe Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
- 11.3.7.Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.8.Germany
  - 11.3.8.1.Overview
  - 11.3.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3.Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4.Germany Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.3.8.5.Germany Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.3.8.6.Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.9.Italy
  - 11.3.9.1.Overview
  - 11.3.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3.Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4.Italy Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.3.9.5.Italy Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.3.9.6.Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.10.United Kingdom
  - 11.3.10.1.Overview
  - 11.3.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3.United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4.United Kingdom Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.3.10.5.United Kingdom Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.3.10.6.United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.11.France
  - 11.3.11.1.Overview
  - 11.3.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3.France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4.France Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.3.11.5.France Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.3.11.6.France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.12.Russia
  - 11.3.12.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2.Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.12.3.Russia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.3.12.4.Russia Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.3.12.5.Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.13.Netherlands
  - 11.3.13.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2.Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.13.3.Netherlands Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.3.13.4.Netherlands Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.3.13.5.Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.14.Sweden
  - 11.3.14.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2.Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.14.3.Sweden Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.3.14.4.Sweden Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.3.14.5.Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.15.Poland
  - 11.3.15.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2.Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.15.3.Poland Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.3.15.4.Poland Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.3.15.5.Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.3.16.Rest of Europe
  - 11.3.16.1.Overview
  - 11.3.16.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3.Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4.Rest of the Europe Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.3.16.5.Rest of the Europe Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.3.16.6.Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.4.Asia Pacific (APAC)
- 11.4.1.Overview
- 11.4.2.Pericardium Diseases Key Manufacturers in Asia Pacific
- 11.4.3.Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4.Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.4.5.Asia Pacific Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
- 11.4.6.Asia Pacific Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
- 11.4.7.Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.8.India
  - 11.4.8.1.Overview
  - 11.4.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3.India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4.India Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.4.8.5.India Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.4.8.6.India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.9.China
  - 11.4.9.1.Overview
  - 11.4.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3.China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4.China Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.4.9.5.China Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.4.9.6.China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.10.Japan
  - 11.4.10.1.Overview
  - 11.4.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3.Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4.Japan Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.4.10.5.Japan Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.4.10.6.Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.11.South Korea
  - 11.4.11.1.Overview
  - 11.4.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3.South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4.South Korea Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.4.11.5.South Korea Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.4.11.6.South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.12.Australia
  - 11.4.12.1.Overview
  - 11.4.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3.Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4.Australia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.4.12.5.Australia Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.4.12.6.Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.13.Thailand
  - 11.4.13.1.Overview
  - 11.4.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3.Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4.Thailand Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.4.13.5.Thailand Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.4.13.6.Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.14.Indonesia
  - 11.4.14.1.Overview
  - 11.4.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3.Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4.Indonesia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.4.14.5.Indonesia Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.4.14.6.Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.15.Philippines
  - 11.4.15.1.Overview
  - 11.4.15.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3.Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4.Philippines Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.4.15.5.Philippines Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.4.15.6.Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.4.16.Rest of APAC
  - 11.4.16.1.Overview
  - 11.4.16.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3.Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4.Rest of APAC Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.4.16.5.Rest of APAC Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.4.16.6.Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.5.Latin America
- 11.5.1.Overview
- 11.5.2.Pericardium Diseases Key Manufacturers in Latin America
- 11.5.3.Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4.Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.5.5.Latin America Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
- 11.5.6.Latin America Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
- 11.5.7.Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.8.Brazil
  - 11.5.8.1.Overview
  - 11.5.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3.Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4.Brazil Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.5.8.5.Brazil Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.5.8.6.Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.9.Mexico
  - 11.5.9.1.Overview
  - 11.5.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3.Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4.Mexico Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.5.9.5.Mexico Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.5.9.6.Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.10.Argentina
  - 11.5.10.1.Overview
  - 11.5.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3.Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4.Argentina Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.5.10.5.Argentina Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.5.10.6.Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.11.Colombia
  - 11.5.11.1.Overview
  - 11.5.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3.Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4.Colombia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.5.11.5.Colombia Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.5.11.6.Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.5.12.Rest of LATAM
  - 11.5.12.1.Overview
  - 11.5.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3.Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4.Rest of LATAM Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.5.12.5.Rest of LATAM Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.5.12.6.Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
11.6.Middle East and Africa
- 11.6.1.Overview
- 11.6.2.Pericardium Diseases Key Manufacturers in Middle East and Africa
- 11.6.3.Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4.Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 11.6.5.Middle East and Africa Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
- 11.6.6.Middle East and Africa Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
- 11.6.7.Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.8.Saudi Arabia
  - 11.6.8.1.Overview
  - 11.6.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3.Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4.Saudi Arabia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.6.8.5.Saudi Arabia Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.6.8.6.Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.9.United Arab Emirates
  - 11.6.9.1.Overview
  - 11.6.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3.United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4.United Arab Emirates Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.6.9.5.United Arab Emirates Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.6.9.6.United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.10.Israel
  - 11.6.10.1.Overview
  - 11.6.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3.Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4.Israel Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.6.10.5.Israel Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.6.10.6.Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.11.Turkey
  - 11.6.11.1.Overview
  - 11.6.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3.Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4.Turkey Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.6.11.5.Turkey Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.6.11.6.Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.12.Algeria
  - 11.6.12.1.Overview
  - 11.6.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3.Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4.Algeria Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.6.12.5.Algeria Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.6.12.6.Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.13.Egypt
  - 11.6.13.1.Overview
  - 11.6.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3.Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4.Egypt Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.6.13.5.Egypt Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.6.13.6.Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 11.6.14.Rest of MEA
  - 11.6.14.1.Overview
  - 11.6.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3.Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4.Rest of MEA Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  - 11.6.14.5.Rest of MEA Market Size and Forecast, By Treatment Approach, 2019 - 2032 (US$ Million)
  - 11.6.14.6.Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12.Key Vendor Analysis- Pericardium Diseases Industry

12.1.Competitive Dashboard
12.2.Company Profiles
- 12.2.1.Kiniksa Pharmaceuticals
- 12.2.2.Pfizer Inc.
- 12.2.3.Medtronic
- 12.2.4.Bayer AG
- 12.2.5.AstraZeneca Plc
- 12.2.6.Sanofi
- 12.2.7.Johnson and Johnson Services, Inc.
- 12.2.8.Merck & Co., Inc.
- 12.2.9.Allergan Plc.
- 12.2.10.Novartis AG
- 12.2.11.Perkin Elmer Inc.
- 12.2.12.Integra Lifesciencesk
- 12.2.13.Others

13.360 Degree Analyst View

14.Appendix

14.1.Research Methodology
14.2.References
14.3.Abbreviations
14.4.Disclaimer
14.5.Contact Us